Treatment Strategies for the Management of LS-SCLC and NSCLC
FACE-OFF: Team Phantoms vs Team Accelerators: Treatment Strategies for the Management of LS-SCLC and NSCLC

Featured Video Clinical Scenario: When Would You Offer LCT?
Panelists discuss how the decision to offer local consolidative therapy in oligometastatic non–small cell lung cancer depends on multiple factors including PET scan activity at 6 months, the feasibility of rendering patients with no evidence of disease, multidisciplinary collaboration, and the emerging need for a “third box” treatment category beyond curative and palliative intent that addresses preemptive strikes against limited progressive sites to prolong survival.  

Unlock better outcomes for patients on adjuvant CDK4/6 therapy.
Education Alert
Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence
1.00 CME / ABIM MOC
What's your strategy for managing patients on adjuvant CDK4/6 therapy? Expert faculty offer essential tips on managing AEs and supporting patient adherence.

 

Learn to integrate endoscopic findings, biomarkers, and patient outcomes for better IBD treatment decisions
Bridging the Gap in IBD: Patient Simulations for Enhanced Clinical Decision Making
1.00 CME / ABIM MOC
Discover how integrating endoscopic findings, biomarkers, and patient-reported outcomes can transform your treatment decisions
 

Preventing Moderate to Severe Dermatologic Adverse Events in First-Line EGFR-Mutant Advanced NSCLC Treated With Amivantamab Plus Lazertinib: Early Success of the COCOON Trial
Alexander Spira, MD, PhD, FACP, FASCO, and Randi Rabin, MPH, MSc, PA-C, discuss how proactive dermatologic adverse event management—specifically through the COCOON protocol—enhances treatment adherence, reduces toxicity, and improves quality of life for patients with EGFR-mutant non–small cell lung cancer receiving amivantamab plus lazertinib.


Featured Video
 

See how RDN improves outcomes in hypertension management
Education Alert
Long-Term Results With Renal Denervation When Guideline Recommendations Are Followed
0.50 CME / ABIM MOC
Explore how guideline-based RDN leads to better outcomes in patients with uncontrolled or resistant hypertension.

Education Alert
Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions
0.50 CPD
Experts discuss what you need to know to support your NF1-associated PNs patients.

時        間：114年9月27日(六) 13:15~17:00 (視訊)
地        點:   臺灣血液腫瘤藥學會YouTube頻道線上
主辦單位：臺灣血液腫瘤藥學會
協辦單位：文德藥業有限公司、台灣塩野義製藥股份有限公司
注意事項：
1.本研討會採用GOOGLE簽到，須完成簽到、課後滿意度及簽退，方能獲得學分。
2.報名開始日：即日起至9月24日
3.若有相關課程問題，請洽研討會聯絡人任冠臻小姐。E-mail: twhopa@gmail.com


---請使用海報連結掃碼填單報名---